Regne Unit - anglès - MHRA (Medicines & Healthcare Products Regulatory Agency)

morningside healthcare ltd - dapsone - oral tablet - 100mg

Regne Unit - anglès - MHRA (Medicines & Healthcare Products Regulatory Agency)

morningside healthcare ltd - dapsone - oral tablet - 50mg

Estats Units - anglès - NLM (National Library of Medicine)

cosette pharmaceuticals, inc. - dapsone (unii: 8w5c518302) (dapsone - unii:8w5c518302) - dapsone gel, 5%, is indicated for the topical treatment of acne vulgaris. none. risk summary there are no available data on dapsone gel, 5%, use in pregnant women to inform a drug-associated risk for adverse developmental outcomes. in animal reproduction studies, oral doses of dapsone administered to pregnant rats and rabbits during organogenesis that resulted in systemic exposures more than 250 times the systemic exposure at the maximum recommended human dose (mrhd) of dapsone gel, 5%, resulted in embryocidal effects. when orally administered to rats from the onset of organogenesis through the end of lactation at systemic exposures approximately 400 times the exposure at the mrhd, dapsone resulted in increased stillbirths and decreased pup weight [see data] . the estimated background risks of major birth defects and miscarriage for the indicated population are unknown. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognize

Regne Unit - anglès - MHRA (Medicines & Healthcare Products Regulatory Agency)

alliance healthcare (distribution) ltd - dapsone - oral tablet - 100mg

Regne Unit - anglès - MHRA (Medicines & Healthcare Products Regulatory Agency)

waymade healthcare plc - dapsone - oral tablet - 100mg

Regne Unit - anglès - MHRA (Medicines & Healthcare Products Regulatory Agency)

mawdsley-brooks & company ltd - dapsone - oral tablet - 100mg

Estats Units - anglès - NLM (National Library of Medicine)

northstar rx llc - dapsone (unii: 8w5c518302) (dapsone - unii:8w5c518302) - dapsone gel, 5%, is indicated for the topical treatment of acne vulgaris. none. risk summary there are no available data on dapsone gel, 5%, use in pregnant women to inform a drug-associated risk for adverse developmental outcomes. in animal reproduction studies, oral doses of dapsone administered to pregnant rats and rabbits during organogenesis that resulted in systemic exposures more than 250 times the systemic exposure at the maximum recommended human dose (mrhd) of dapsone gel, 5%, resulted in embryocidal effects. when orally administered to rats from the onset of organogenesis through the end of lactation at systemic exposures approximately 400 times the exposure at the mrhd, dapsone resulted in increased stillbirths and decreased pup weight [see data] . the estimated background risks of major birth defects and miscarriage for the indicated population are unknown. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is

Estats Units - anglès - NLM (National Library of Medicine)

allergan, inc. - dapsone (unii: 8w5c518302) (dapsone - unii:8w5c518302) - dapsone 50 mg in 1 g - aczone ® gel, 5%, is indicated for the topical treatment of acne vulgaris. none. risk summary there are no available data on aczone gel, 5%, use in pregnant women to inform a drug-associated risk for adverse developmental outcomes. in animal reproduction studies, oral doses of dapsone administered to pregnant rats and rabbits during organogenesis that resulted in systemic exposures more than 250 times the systemic exposure at the maximum recommended human dose (mrhd) of aczone gel, 5%, resulted in embryocidal effects. when orally administered to rats from the onset of organogenesis through the end of lactation at systemic exposures approximately 400 times the exposure at the mrhd, dapsone resulted in increased stillbirths and decreased pup weight [see data] . the estimated background risks of major birth defects and miscarriage for the indicated population are unknown. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies

Estats Units - anglès - NLM (National Library of Medicine)

taro pharmaceuticals u.s.a., inc. - dapsone (unii: 8w5c518302) (dapsone - unii:8w5c518302) - dapsone gel, 7.5%, is indicated for the topical treatment of acne vulgaris in patients 9 years of age and older. none. risk summary there are no available data on dapsone gel, 7.5%, use in pregnant women to inform a drug-associated risk for adverse developmental outcomes. the systemic absorption of dapsone in humans following topical application is low relative to oral dapsone administration [see clinical pharmacology (12.3)] . in animal reproduction studies, oral doses of dapsone administered to pregnant rats and rabbits during organogenesis that resulted in systemic exposures more than 400 times the systemic exposure at the maximum recommended human dose (mrhd) of dapsone gel, 7.5%, resulted in embryocidal effects. when orally administered to rats from the onset of organogenesis through the end of lactation at systemic exposures approximately 500 times the exposure at the mrhd, dapsone resulted in increased stillbirths and decreased pup weight [see data]. the estimated background risks of major birth defect

Estats Units - anglès - NLM (National Library of Medicine)

taro pharmaceuticals u.s.a., inc. - dapsone (unii: 8w5c518302) (dapsone - unii:8w5c518302) -  dapsone gel, 7.5%, is indicated for the topical treatment of acne vulgaris in patients 9 years of age and older. none. risk summary there are no available data on dapsone gel, 7.5%, use in pregnant women to inform a drug-associated risk for adverse developmental outcomes. the systemic absorption of dapsone in humans following topical application is low relative to oral dapsone administration [see clinical pharmacology (12.3)] . in animal reproduction studies, oral doses of dapsone administered to pregnant rats and rabbits during organogenesis that resulted in systemic exposures more than 400 times the systemic exposure at the maximum recommended human dose (mrhd) of dapsone gel, 7.5%, resulted in embryocidal effects. when orally administered to rats from the onset of organogenesis through the end of lactation at systemic exposures approximately 500 times the exposure at the mrhd, dapsone resulted in increased stillbirths and decreased pup weight [see data] . the estimated background risks of major birth def